Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized high-dose busulfan dosing before hematopoietic stem cell transplantation
2004-003854-25Phase 4Completed
- Sponsor
- Interní grantová agentura Ministerstva zdravotnictví
- Start
- Jan 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of busulfan in hematopoietic malignancies and Hematopathy, sponsored by Interní grantová agentura Ministerstva zdravotnictví. Primary endpoints: Busulfan dose adjustment based on pharmacokinetic exposure and Toxicity evaluation. Started Jan 2005; status: completed.
02
Drugs
busulfan
03
Conditions
hematopoietic malignanciesHematopathy
Beyond the preview
Go deeper on 2004-003854-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003854-25.